Original ResearchLLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma
Under a Creative Commons license
open access
Graphical abstract
Keywords
Pancreatic Cancer
Gemcitabine
Oncostatin M Receptor
SP1 Signaling
Abbreviations used in this paper
cDNA
complementary DNA
ChIP
chromatin immunoprecipitation
CSC
cancer stem cell
Dlg
discs large protein
EMT
epithelial-mesenchymal transition
ERK2
extracellular signal-regulated kinase 2
hENT1
human equilibrative nucleoside transporter 1
HPDE
human pancreatic ductal epithelial
IC50
median inhibitory concentration
IHC
immunohistochemistry
Lgl
lethal giant larvae
LLGL1
lethal giant larvae homolog 1
MTT
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
OSM
oncostatin M
OSMR
oncostatin M receptor
PDAC
pancreatic ductal adenocarcinoma
Pol II
RNA polymerase II
qRT-PCR
quantitative reverse-transcription polymerase chain reaction
RNAi
RNA interference
siLLGL1
small interfering lethal giant larvae homolog 1
siRNA
small interfering RNA
Sp1
specificity protein 1
SWH
Salvador/Warts/Hippo
TGF
transforming growth factor
Cited by (0)
Conflicts of interest The authors disclose no conflicts.
Funding Supported by grants from the National Natural Science Foundation of China (81672323), the General Research Fund, Research Grants Council of Hong Kong (14171217 and 14120618), and a direct grant from The Chinese University of Hong Kong (Y.C.).
- ∗
Authors contributed equally
- §
Authors contributed equally.
© 2020 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute.